基本信息
views: 42
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Pirkko Härkönen, M.D., Ph.D.
Professor Emerita
Pirkko Härkönen graduated in medicine (M.D.) from the University of Turku, Finland, and obtained her Ph.D. degree in experimental endocrinology from the same university (1983). She was trained in cancer biology as a post-doctoral fellow at the Imperial Cancer Research Fund (now Cancer Research UK), London, UK (1985-1987). She then returned to the University of Turku to start her laboratory and worked in various university positions, then as a Senior Researcher at the Academy of Finland (1994-2000), and Professor of Medical Cell Biology at the University of Turku. In 2002, she received a position as a Professor of Tumor Biology at Lund University, Sweden, and in 2010 as a Professor of Medical Cell Biology at the University of Turku. She was also Head of the Institute of Biomedicine (2010-2016). She retired in 2016 and has since worked as Professor Emerita at the Institute of Biomedicine and the FICAN West Cancer Centre, at the University of Turku.
The research work of Prof. Härkönen has concerned with the growth mechanisms of human breast and prostate cancer using experimental in vivo and in vitro models and analysis of clinical tumor specimens. including patient-derived tumor models. She has particularly focused on the FGF/FGFR mediated tumor growth, progression, and metastasis and the role of the FGF/FGFR pathways in hormonal regulation and the development of hormone resistance. The previous work also widely included studies on the mechanisms and targets of selective estrogen receptor modulators in the normal and malignant human breast. Prof. Härkönen has published more than 150 peer-reviewed research papers, supervised 23 completed doctoral theses, and mentored several post-doctoral fellows. She has extensive experience in teaching students in the Medical and Dental curricula as well as in the Bachelor`s program and the International Master`s Degree program in the Biomedical Sciences. Besides several positions of trust, she was the first director of the National Drug Discovery Graduate School. She is a founding member of a drug discovery company and two contract research service companies (CROs). Her research group has critically contributed to the discovery process of ospemifene, a drug approved for clinical use (Osphena), and a transfer of clinically relevant disease models to local spin-off companies.
Research Interests
Papers共 214 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Sanna S. Virtanen, Anu Kukkonen-Macchi,Minna Vainio,Kati Elima,Pirkko L. Härkönen,Sirpa Jalkanen,Gennady G. Yegutkin
crossref(2023)
T. E. Kähkönen,M. Toriseva,N. Petruk, A.-R. Virta, A. Maher, N. Eigéliené,J. Kaivola, P. Boström, I. Koskivuo,M. Nees, J. M. Tuomela,K. K. Ivaska,
S. Umbreen, R.E. Steele,N. Poulose, M. Congiano,S. Afshan, I. Beumer,M. Nees,P. Harkonen, N. Mccabe,S. Mcdade, I.G. Mills
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn